106 / 1631
Chimeric Antigen Receptors T cells
(CAR-T) in Cancer Therapy
•
Adoptive cellular therapies such as tumour infiltrating lymphocytes
and TCR gene-modified T-cells have demonstrated success in recent
clinical trials
•
Problem : Tumours often down-regulate MHC molecules and tumour
specific antigens are often not known.
•
Solution : Chimeric antigen receptors target cell surface proteins
using antibody based recognition systems can overcome some of
these problems.